EXAS Share Price

Open 53.99 Change Price %
High 57.95 1 Day 4.89 9.76
Low 53.72 1 Week 0.00 0.00
Close 54.99 1 Month 7.58 15.99
Volume 6591655 1 Year 37.31 211.03
52 Week High 57.95
52 Week Low 13.05
EXAS Important Levels
Resistance 2 58.91
Resistance 1 57.30
Pivot 55.55
Support 1 52.68
Support 2 51.07
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

EXACT Sciences Corporation (NASDAQ: EXAS)

EXAS Technical Analysis 5
As on 31st Oct 2017 EXAS Share Price closed @ 54.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 30.49 & Strong Buy for SHORT-TERM with Stoploss of 44.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
EXAS Target for November
1st Target up-side 61.94
2nd Target up-side 66.81
3rd Target up-side 71.68
1st Target down-side 48.04
2nd Target down-side 43.17
3rd Target down-side 38.3
EXAS Other Details
Segment EQ
Market Capital 594952448.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.exactsciences.com
EXAS Address
EXAS
441 Charmany Drive
Madison, WI 53719
United States
Phone: 608-284-5700
Fax: 608-284-5701
EXAS Latest News
Interactive Technical Analysis Chart EXACT Sciences Corporation ( EXAS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on EXACT Sciences Corporation
EXAS Business Profile
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.